Company Information
CIN
Status
Date of Incorporation
20 November 1987
State / ROC
Bangalore / ROC Bangalore
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 September 2023
Paid Up Capital
86,801,898
Authorised Capital
110,000,000
Directors
Vishnukant Chaturbhuj Bhutada
Director/Designated Partner
over 2 years ago
over 2 years ago
Kamal Kishore Sharma
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Anita Bandyopadhyay
Director/Designated Partner
over 3 years ago
over 3 years ago
Hetal Madhukant Gandhi
Director/Designated Partner
about 4 years ago
about 4 years ago
Kalakota Reddy Sharath
Director/Designated Partner
about 6 years ago
about 6 years ago
Sirisha Chintapalli
Director/Designated Partner
about 6 years ago
about 6 years ago
Ajeet Singh Karan
Director
about 14 years ago
about 14 years ago
Pramod Kasat
Director
about 15 years ago
about 15 years ago
Atim Kabra
Director
over 18 years ago
over 18 years ago
Carlton Gerard Pereira
Director
over 18 years ago
over 18 years ago
Om Prakash Inani
Director/Designated Partner
over 37 years ago
over 37 years ago
Past Directors
Arvind Vasudeva
Additional Director
over 4 years ago
over 4 years ago
Krishna Chaitanya Venkata Vakkalanka
Company Secretary
about 6 years ago
about 6 years ago
Amit Chander
Additional Director
over 6 years ago
over 6 years ago
Madhusudhan Reddy
Company Secretary
almost 9 years ago
almost 9 years ago
. Namrata Baldwa
Director
about 10 years ago
about 10 years ago
Venugopal Loya
Director
about 23 years ago
about 23 years ago
Patents
The present application provides pharmaceutical composition/s comprising pemetrexed dipotassium hydrate and its uses thereof.
The invention also provides process for preparing lyophilized compositions of pemetrexed dipotassium hemiheptahydrate.
ABSTRACT
The present invention relates to novel salt of 3,4-diaminopyridine as 3,4-diaminopyridine dihydrochloride (or Amifampridine dihydrochloride), useful in the preparation of pharmaceutical composition thereof. The present application also relates toan improved process for the preparation of substantially pure...
The present invention provide processes for the preparation of Bendamustine hydrochloride monohydrate of formula (I)
The present application also provides a process of purification of Bendamustine hydrochloride or monohydrate to get substantially pure Bendamustine hydrochloride monohydrate crystalline Form-SM. Th...
A process for preparing amorphous Cabazitaxel (I) characterized by X-ray powder
(I) diffraction pattern as per Fig-1 comprising the steps of-
a) providing a solution of (2a,5y?,7^,10/?,13a)-4-acetoxy-13-({(2i?,35)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-7,10-dimethoxy-9-oxo-5...
The present invention relates to a process for preparation of Echothiophate Iodide (I). Echothiophate Iodide (I) obtained by the process of the present invention is obtained as new crystalline form designated as Form-SET.
(I)
The process for preparation of Echothiophate Iodide (I) according to present invention i...
AN IMPROVED PROCESS FOR THE PREPARATION OF ERLOTINIB HYDROCHLORIDE
ABSTRACT
The present invention relates to an improved process for the preparation Erlotinib or its hydrochloride salt of Formula (I).
The present invention relates to a process for the preparation of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one or Ibrutinib of Formula (I).
(I)
The present invention further relates to a process for the preparation highly pure 1-[(3R)-3-[4-amino-3-(4-...
The present invention relates to a process for the preparation of L-alanine,N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1methylethoxy]methyl]phenoxyphosphinyl]-1-methylethyl ester, (2E)-2-butenedioate or Tenofovir Alafenamide fumarate(I).
(I)
The present invention further relates to a process for the enantiomerica...
The present invention provides 10-Propargyl-10-Deazaaminopterin (I) crystalline polymorphic form designated as Form-SPR and its process for preparation thereof.
The present application also provides 10-Propargyl-l0-Deazaaminopterin (I) crystalline polymorphic Form-SPR useful as an active pharmaceutical ingredient i...
PROCESS FOR PREPARATION OF HIGHLY PURE GEFITINIB
ABSTRACT
The present invention relates to a process for the preparation of 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin)propoxy] or Gefitinib of Formula (I).
(I)
The present invention further relates to a process for the pur...
A present invention relates to a process for the preparation of Rivastigmine tatrate and its intermediates.
NOVEL POLYMORPHS OF AXITINIB
ABSTRACT
The present invention relates to novel crystalline polymorphic forms of Axitinib Formula (I).
(I)
Said crystalline forms may be useful in the improved preparation of oral dosage forms for the treatment of cancer.
The present invention relates toaprocess for the preparation of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N"propylsulfamide or Macitentan of Formula (I).
(I)
The present invention further relates to a process for the preparation highly pure N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-p...
ABSTRACT
The present invention relates tonovel crystalline forms of L-alanine,N-[(S)-[[(1R)-2-(6-amino-9H-purin-9-yl)-1methylethoxy]methyl]phenoxyphosphinyl]-1-methylethyl ester, (2E)-2-butenedioate or Tenofovir Alafenamide hemi fumarate(I).
(I)
The present invention further relates to a process for the ena...
The invention relates to a dispersible tablet composition comprising a therapeutically effective amount of Ursodiol or its pharmaceutically acceptable salts thereof, with one or more pharmaceutically acceptable excipients, having disintegration time of less than 2 minutes in a dispersion medium.
Said dispersible ...
PROCESS FOR PREPARATION OF ENZALUTAMIDE
ABSTRACT
The present application relates to a process for preparation of Enzalutamide (I).
(I)
The present application also relates to a novel process for the preparation of Enzalutamide intermediate useful in the industrially viable synthesis of Enzalutamide.
...
ABSTRACT
The present invention relates to a process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide or Regorafenib of Formula (I).
(I)
The present invention further relates to a process for the purification of 4-[4-({[4-chlor...
The present invention relates to a process for preparation of crystalline 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide(I).
The crystalline form of 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide designated as Form- SV, obtained by the process/es according to the present ...
The present application provides pharmaceutical compositions derived from pemetrexed dipotassium Nonahydrate and its process thereof.
The present application also provides a method of treating cancer by administering intravenously the reconstituted lyophilized compositions into a patient in need thereof.
...
The present invention relates to an improved process for preparation of Paclitaxel of Formula (I).
(I)
The present invention also relates to an improved process for the preparation of Paclitaxel intermediate.
Abstract
The present invention relates to novel pharmaceutically acceptable glucuronic acid addition salt of Sunitinib (I) or its solvate thereof.
/
The present invention further relates to the processes for preparation of the said glucuronic acid addition salt of Sunitinib. The glucuronic acid addition salt o...
The present invention provide process of preparation of (2R, 3S)-N-carboxy-3-phenylisoserine, N- tert-butyl ester, 13-ester with 5(β)-20-epoxy-l,2(α), 4,7(β), 10(β), 13(α)-hexa hydroxy tax-11-en-9- one 4-acetate 2-benzoate or docetaxel and its trihydrate (I)
FIG.
The present invention relates to amorphous 4-(3-(4-cyano-3-(trifluoromcthyl) phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1 –y1)-2-fluoro-N-methylbenzarnidc (I)
and process for preparation thereof.
The invention further relates to pharmaceutical compositions comprising amorphous 4-(3-(4-cyano-3-(trifluoromet...
The present invention provides an improved process for preparing N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-l-piperazinyl]-2-methyl-4-pyrimidinyl] amino]-5-thiazole carboxamide monohydrate or Dasatinib monohydrate (Formula A).
The present invention relates to process for the preparation of highly pure Lenalidomide (I).
(I)
The present invention further relates to a pharmaceutical compositions comprising highly pure Lenalidomide useful for the treatment of cancer.
The present invention relates to novel crystalline polymorphic forms of Afatinib dimaleateof Formula (I).
(I)
Said crystalline forms may be useful in the improved preparation of oral dosage forms for the treatment of cancer.
ABSTRACT
The present invention relates to a process for the preparation of compound of Formula (I).
(I)
The present invention relates to a process for the preparation of highly pure Pomalidomide (I).
The present invention further related to highly pure Pomalidomide useful in the treatment of cancer.
...
The present invention provides Crystalline 5-Azacytidine (I) designated as Form-SA-1 and process for preparing thereof.
The present application also provides lyophilized formulation comprising crystalline 5-Azacytidine Form-SA-1 useful in the treatment of cancer, and methods of preparing said lyophilized formulatio...
ABSTRACT
The present invention relates to an improved process for the preparation Sofosbuvir Formula (I).
(I)
The present further relates to Sofosbuvir having a purity of greater than 99.5%.
ABSTRACT
The present invention relates to an oral pharmaceutical composition comprising crystalline axitinib wherein oral composition is optionally coated, which coating is devoid of any metal oxides.
ABSTRACT
The present invention relates to a pharmaceutical composition comprising fingolimod and/or pharmaceutical acceptable salt thereof and dicalcium phosphate. The composition is preferably formulated in a form of a powder for oral administration filled into capsules and/or a compressed tablet.
...
The present invention provides novel crystalline form of docetaxel trihydrate designated as Form-VK and process for preparation thereof.
The present application also provides a substantially pure trihydrate crystalline product obtained by the process according to the present invention having characteristic XRPD p...
ABSTRACT
The present invention relates to a process for the preparation of Decitabine of Formula (I).
(I)
The present invention further relates to a stable crystalline Form of Decitabine designated as Form SDE, which commercially viable for preparing stable dosage forms.
The present invention relates to novel pharmaceutically acceptable substituted aryl acrylic acid addition salts of Sunitinib (I) or its hydrate or solvate thereof.
The present invention further relates to processes for preparation of the said substituted aryl acrylic acid addition salts of Sunitinib (I). The presen...
The present invention relates to novel pharmaceutically acceptable glucuronic acid addition salt of Dasatinib (I) or its hydrate or solvate thereof.
The present invention further relates to the processes for preparation of the said glucuronic acid addition salt of Dasatinib. The glucuronic acid addition salt of D...
Abstract
The present invention provides diisopropyl ether solvate of (2a,5p,7p,10p,13a)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate or Cabazitaxel (I) and process for its preparation.
The present applica...
The present invention provides a stable lyophilized composition comprising 5-Azacytidine Form I, and process for preparing thereof.
The present invention provides a stable lyophilized composition comprising 5-Azacytidine Form I, and the methods of using a stable lyophilized composition comprising Crystalline 5-Azac...
The present invention provides Di potassium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido) pentanedioate (I)
and its hydrates useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.
The present invention also provides process f...
ABSTRACT
The present invention relates to a process for preparation of stable Dasatinib base (I).
(I)
The present invention further, relates to a process for preparation of amorphous Dasatinib base (I).
Said stable Dasatinib base (I) may be useful in preparing pharmaceutical dosage form for the treatment of c...
The present invention provides crystalline pemetrexed dipotassium hemiheptahydrate (I) -
characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 20°peaks selected from the XRPD peak set of 5.00,13.70,14.90, 15.20,16.90, 20.00, 20.50, 21.40,23.6, 24.2,25.10, 27.5 and 28.30 ± 0.20 29...
The present invention relates to a process for preparation of a novel crystalline form of Glucuronic acid addition salt of Sunitinib (I) termed as Form-SG2.
Form-SG2 of Sunitinib Glucuronate (I) is crystalline in nature and is characterized by X-ray powder diffraction pattern comprising of at least three 29° pea...
The present invention provide processes for the preparation of N-[4-Cyano-3-(trifluoro methyl) phenyl]-3-[(4-fluorophenyl) sulphonyl]-2-hydroxy-2-methyl propanamide (I).
The present application also provides a method of purification of N-[4-Cyano-3-(trifluoro methyl) phenyl]-3-[(4-fluorophenyl) sulphonyl]-2-hydro...
The present invention provides process for preparation of crystalline Bortezomib (la) as its monohydrate which is designated as crystalline Form-SB and characterized by having water content ranging between 5.5- 8.0 % w/w; X-ray powder diffraction pattern comprising characteristic 20° peaks selected from the XRPD pea...
The present invention provides (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino] -2-hydroxy-3 -phenylpropanoyl} oxy)-1 -hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-1 l-en-2-yl benzoate or Cabazitaxel (I) stable crystalline Form-SC and process for its preparation.
The present application a...
Disclosed is a process for the preparation of malic acid salt of N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-l,2-dmydro-2-oxo-3H-mdol-3-ylidine)methyl]-2,4-dimethyl-lH-pyrrole-3-carboxamide of Formula I.
The present invention relates to the process for the preparation of polymorph I of sorafenib tosylate using t-Butanol and also using ethyl acetate and polyethylene glycol as solvent
The present invention relates to a novel and key intermediate 2,2'-diflluoro-2-deoxy-3,5-di-o-protected-1-trihaloacetimido-D-ribofuranose of formula (Va), its use in the preparation of 2,2'-difluoro-2-deoxy-ribonucleoside by contactiong with suitably protected silylated compound of the required nucleobase to obtain...
The present invention provides novel l-trihaloacetimido-2-deoxy-2,2'-difluoro-3,5-di-O-protected ribose intermediates. The compounds are useful in the preparation of 2'-deoxy-2,2'- difluoro-beta nucleosides and more particularly 2'-deoxy-2,2'-difluoro-beta cytidine and other beta anomer nucleosides and its salts h...
PROCESS AND INTERMEDIATE OF LETROZOLE
ABSTRACT
The present invention relates to a process for the preparation of Letrozole involving the use of novel intermediate of Formula (I).
The present invention provides crystalline polymorphic forms of Fingolimod HCl (I) and processes for preparation thereof.
The application provides processes for preparation of crystalline polymorphic forms - α β and μ substantially free from process related impurities. The crystalline polymorphic forms of Fingo...
The present invention provide processes for the preparation of (2R, 3S) 2-Benzyloxy-3-tert- butoxy carbonyl amino -3- phenyl propionic acid of formula (I)
The present application also provides a method of purification and isolation of (2R, 3S) 2- Benzyloxy-3-tert-butoxy carbonyl amino -3- phenyl propionic acid
...
The present invention provides Crystalline Strontium ranelate Form-S and process for preparation thereof.
The present application also provides a substantially pure crystalline product obtained by the process according to the present invention having characteristic XRPD peak set of 7.70, 15.33, 16.46, 19.55, 20.11,...
The present invention provides a non-solvated amorphous form of (2 α ,5 β,7 β,10 β,13 α )-4-acetoxy-13-({(2R,3S)-3[ (tert-butoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-l-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-ll-en-2-yl benzoate or Cabazitaxel (I), I'J and process for ...
The present invention relates to the process for the preparation of lenalidomide and its intermediate compound of formula IV.
The present invention relates to process for preparing crystalline Pazopanib HC1 (I) The crystalline form designated as Form- SP of Pazopanib HC1 (I) obtained by the process/es according to the present invention is useful as an anti-cancer agent.
The present invention provides an industrially suitable process for the preparation of substantially pure 4-{4-[({[4-chloro-3-(trifluoromethyl)- phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide or Sorafenib and its tosylate salt, with a suitable impurity profile and without requirement of any addi...
The present invention provides process for preparation of Crystalline Erlotinib HC1 (I) Form-SE
characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 20°peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40,20.65,21.86, 23.5, 31.80, 32.13, 32.80,...
The present invention relates to pharmaceutical compositions comprising Proteasome inhibitors devoid of any pharmaceutically acceptable excipient.
The present invention also relates to process for preparing said compositions useful in the treatment of cancer.
The present invention provides process for preparation of Fingolimod hydrochloride (I).
Fingolimod hydrochloride (I) as Form-β obtained by the process of present invention may be useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of autoimmune related disorder including mult...
The present invention relates to amorphous form of (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide (I) or its pharmaceutically active salts,
and process for preparation thereof.
The invention further relates to pharmaceutical compositions comprising amorphous form of (2-chloro-N-(4-chloro...
The present invention relates to novel intermidiate compounds of formula(la) and is slats therof, wherein R is an amino protecting group,R1 is selected from the group consisting of hydrogen, an alkyl, arralkyl hydroxymethyl, carboxymethyl, acyloxymethyl, trialkysilyl or an N-substituted alkdy amine where nitrogen fo...
The present invention relates to a process for preparation of crystalline Form-SL of Lenalidomide (I).
(I)
The invention also relates to crystalline Form-SL obtained by the process of the present invention, the said Form-SL being substantially pure and characterized by X-ray powder diffraction pattern comprising ...
ABSTRACT
The Present invention provides the orally administrable, disintegrating film dosage forms comprising fingolimod or pharmaceutically acceptable salts or solvates thereof.
The present invention relate to lyophilized formulations comprising 5-azacytidine and process for preparing lyophilized formulations comprising 5-azacytidine.
The present invention relates to a process for preparation of dimethyl-(E)-butenedioate (I).
O (I)
The process for preparation of dimethyI-(E)-butenedioate (I), comprises reaction of Fumaric acid with methanol in the presence of C2-C4 alkanoyl halide as coupling catalyst.
AN IMPROVED PROCESS FOR PREPARATION OF AXITINIB
ABSTRACT
The present invention relates to an improved process for the preparation Axitinib Formula (I).
(I)
The present further relates to Axitinib containing the process related impurities A, B, C, D, E and F collectively below 0.3% and having a purity of greate...
ABSTRACT
ENZALUTAMIDE HARD GELATIN CAPSULE COMPOSITIONS
The present invention relates to the pharmaceutical compositions, including unit dosage forms specifically hard gelatin capsules, comprising Enzalutamide as well as process for producing such compositions.
The present invention provides a stable liquid bendamustine pharmaceutical composition comprising: (i) bendamustine, a pharmaceutically acceptable salt, and/or a hydrate thereof, (ii) diethylene glycol monoethyl ether, and (iii) a pH adjusting agent, wherein the pharmaceutical composition has a pH of about 3.0 to ab...
The present invention relates to an aqueous ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, the solution comprising at least 0.5 w/v% brinzolamide dissolved in the solution; hydroxy-propyl-ß-cyclodextrin; polyvinyl caprolactam-polyvinyl ...
[065] The present invention provides the method and/or compositions for administering a therapeutically effective amount of ursodeoxycholic acid (UDCA) intravenously for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases. The present invention also relates to methods of intraven...
ABSTRACT
SPRAY COMPOSITIONS OF CHITOSAN FOR WOUND HEALING
The present invention relates to topical spray compositions comprising chitosan and the process for preparation thereof. The topical spray compositions comprising chitosan are used for the treating burn wounds, wounds resulting from chemical burns, wou...
ABSTRACT:
The present invention relates to stable liquid pharmaceutical composition of decitabine comprising decitabine and at least one pharmaceutically acceptable excipient, wherein moisture content of the liquid composition is less than about 2.0% by weight. The invention further relates to stable liquid compos...
OPHTHALMIC COMPOSITIONS OF BRINZOLAMIDE
The present invention relates to an aqueous ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, the solution comprising at least 0.5 w/v% brinzolamide dissolved in the solution; hydroxy-propyl-ß-cyclo...
ABSTRACT
ORAL DISINTEGRATING FILM COMPOSITIONS OF PARACETAMOL
The present invention relates to fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof as an active ingredient whose bitter taste is to be masked. More specifically, the present invention relates to a ...
ABSTRACTPHARMACEUTICAL COMPOSITIONS OF LENVATINIBThe present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group con...
ABSTRACT
The present invention relates to novel crystalline and amorphous polymorphic forms of Ribociclib(I) mono succinate.
(I)
Said crystalline forms may be useful in the improved preparation of oral dosage forms for the treatment of cancer.
ABSTRACT
The present invention relates to novel stable crystalline form of Rucaparib (I) camsylate and methods of preparing the same
(I)
The present invention further relates to process for the amorphous Rucaparib (I) camsylate.
Said crystalline form may be useful in the improved preparation of oral dosage ...
The present invention relates to an improved process for the preparation of compound of formula (I) and its pharmaceutical acceptable salts thereof.
The present invention relates to a process for the preparation of highly pure Lenvatinib (I).
Abstract
The present invention relates to an amorphous form of Panobinostat Lactate hydrate. In particular, the present invention relates to processes for the preparation of amorphous form of Panobinostat Lactate. More particular the present invention relates to the pharmaceutical composition comprising an amorphou...
ABSTRACT
OPHTHALMIC COMPOSITIONS OF TAMARIND SEED POLYSACCHARIDE
The present invention relates to compositions containing tamarind seed polysaccharide for corneal and conjunctival healing and the process for preparation thereof. In embodiments of the invention, ophthalmic composition is an aqueous ophthalmic solu...
ABSTRACT
ORALLY DISINTEGRATING STRIP OF CALCIUM SUPPLEMENTS
The present invention provides herein, pharmaceutical composition of orally disintegrating strips consisting essentially of a therapeutically effective amount of microcrystalline hydroxyapatite complex and an excipient that facilitates oral administrati...
The present invention relates to an improved process for the preparation of compound of formula (I) and its pharmaceutical acceptable salts thereof.
The present invention relates to a process for the preparation of highly pure Venetoclax (I).
The present invention relates to an improved process for the preparation of compound of formula (I) and its pharmaceutical acceptable salts thereof.
The present invention relates to a process for the preparation of highly pure Temozolomide (I).
STABLE MELPHALAN LIQUID INJECTABLE FORMULATIONS
The present invention relates to a stable, non-aqueous liquid, formulation consisting essentially of melphalan, or a pharmaceutical acceptable salt thereof; and one or more solvents selected from group consisting of dimethyl acetamide, polyethylene glycol, ethanol, pr...
[059] The present invention is directed to an injectable pharmaceutical composition comprising (a) ursodeoxycholic acid and (b) sulfobutylether-ß-cyclodextrin. Such compositions exhibit unexpected solubility and stability of ursodeoxycholic acid permitting therapeutic dosages of the ursodeoxycholic acid to be admini...
[00108] ABSTRACT
[00109] CABAZITAXEL LIQUID FORMULATIONS
[00110] The present invention relates to the stable liquid pharmaceutical composition comprising (a) cabazitaxel or a pharmaceutically acceptable salt or solvate thereof, (b) one or more solubilizers selected from the group consisting of soya phosphatidyl ch...
[0053] The present invention relates to a pharmaceutical composition, preferably in form of tablet(s), in particular a dispersible, especially a fast dispersible pharmaceutical composition, preferably in the form of tablet(s), further in particular a water dispersible, especially a fast water-dispersible pharmaceuti...
[062] The present invention relates to oral liquid formulations comprising lenvatinib or pharmaceutically acceptable salts or solvates thereof with improved stability and palatability.
[091] The present invention relates to an injectable composition for extended release of fingolimod comprising a suspension of at least about 0.5 mg/ml of fingolimod, wherein fingolimod release is for at least 7 days and the process for preparation thereof.
The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or s...
ABSTRACT
ACETAZOLAMIDE OPHTHALMIC SOLUTION
The present invention relates to an ophthalmic composition which is an aqueous solution comprising acetazolamide, cyclodextrin, water soluble polymer, a high molecular weight acrylic acid polymer crosslinked with divinyl glycol containing polymer and water and the prese...
The present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group consisting of calcium hydroxide and potassium hydroxide; and its process...
The present invention relates to novel green tea water-soluble film composition comprising (a) green tea extract, (b) water-soluble polymer selected from group consisting of sodium alginate, cross-linked polyacrylate and carrageenan, and (c) additives and the process for the preparation thereof. As per the present i...
The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.
...
ABSTRACT
The present invention relates to novel stable crystalline form of Nilotinib sulfate and methods of preparing the same
Said crystalline form may be useful in the improved preparation of oral dosage forms for the treatment of cancer.
ABSTRACT
The present invention relates to novel stable crystalline and solvate polymorphic forms of Ribociclib(I) mono succinate.
(I)
The present invention further relates to amorphous mono succinate and methods of preparing the same as well as pharmaceutically acceptable salts thereof.
Said crystalli...
The present invention relates to novel green tea water soluble film composition comprising a) green tea extract, b) water soluble polymer mixture consisting of sodium carboxymethyl cellulose and sodium alginate, and c) additives. Green tea is conveniently prepared by dissolving the novel water soluble green tea film...
[0060] The present invention relates to a dispersible tablet comprising at least 70% w/w of abiraterone acetate based on the total weight of the tablet and at least one pharmaceutically excipient selected from group consisting of diluents, binders, surfactants, glidants, disintegrants, lubricants, sweeteners and fla...
[075] The present invention relates to stable orally dissolving formulations e.g., tablets (ODTs) and films (ODFs) comprising prucalopride succinate or pharmaceutically acceptable salts thereof and the process for preparation thereof for the treatment of chronic idiopathic constipation.
ABSTRACT
The present invention relates to an improved process for the preparation of substantially pure Amifampridine phosphate
(I)
The present invention further relates to a substantially pure Amifampridine Phosphate, useful for the preparation of pharmaceutical composition thereof.
...
ABSTRACT
ORAL DISINTEGRATING FILM COMPOSITIONS OF PARACETAMOL
5
The present invention relates to fast dissolving film composition comprising paracetamol or a pharmaceutically acceptable salt thereof as an active ingredient whose bitter taste is to be masked. More specifically, the present invention relates to a fast...
The present invention relates to an improved process for the preparation of compound of formula (I) and its pharmaceutical acceptable salts thereof.
The present invention relates to a process for the preparation of highly pure Eltrombopag (I).
The present invention provides an improved process for the preparation of Cladribine of formula I.
[115] The present invention provides a topical spray composition comprising palmitoylethanolamide and menthol and the process for preparation thereof. The topical spray composition comprising palmitoylethanolamide as per the present invention are used for the treatment of pain and inflammation.
...
[003] The present invention relates to the pharmaceutical composition, preferably capsule dosage form comprising nilotinib free base and the process for preparation thereof. The capsule dosage forms of the present invention comprising nilotinib free base as the active ingredient are bioequivalent to the capsule dosa...
[047] The present invention provides a stable pharmaceutical liquid solution for oral administration comprising lenalidomide and a pharmaceutically acceptable excipient, preferably the solution comprises of at least 1 mg/mL of lenalidomide and more preferably of about 1 mg/mL to about 30 mg/mL of lenalidomide and th...
[036] The present invention provides a pharmaceutical composition comprising (a) a therapeutically effective dose of molnupiravir and (b) a therapeutically effective dose of 2-deoxy-d-glucose (2DG) for treatment of SARS-CoV-2 infection in a patient, and the process for the preparation thereof.
[085] The present invention relates to an orally fast dissolving film formulation comprising rivaroxaban or pharmaceutically acceptable salts thereof and the process for preparation thereof. The present invention further relates to the fast dissolving film formulation comprising rivaroxaban or a pharmaceutically acc...
[068] The present invention provides a single unit dosage form suitable for oral administration to a human comprising, an amount equal to or greater than about 11 mg to about 30 mg of lenvatinib or a pharmaceutically acceptable salt, stereoisomer, prodrug, solvate, hydrate or clathrate, thereof; and a pharmaceutical...
The present invention relates to a process for the preparation of crystalline Bortezomib of formula (I) and its pharmaceutical acceptable salts thereof.
(I)
The present invention relates to a process for the preparation of highly pure crystalline Bortezomib (I).
The present invention relates to an improved process for the preparation of poly (1, 3-alkenes)-block-poly (alkylene oxides) copolymers. Furthermore, this invention also relates to the purification of crude amphiphilic block copolymers PD-b-PAO having oligomers and low molecular weight polymers.
...
[0038] The present invention relates to the orally disintegrating strips comprising ondansetron or its pharmaceutically acceptable salts thereof, polymer mixture consisting of hydroxypropyl methylcellulose and polyvinylpyrrolidone, polysorbate 80 as the surfactant and glycerol as the plasticizer and the process for ...
The present invention relates to novel formulations comprising a sprayable composition comprising tranexamic acid and chitosan for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention and the process for preparation thereof.
...
[061] The present invention relates to the injectable pharmaceutical compositions of nor-UDCA or its pharmaceutically acceptable salts or esters thereof and the process for preparation thereof. More specifically the present invention relates to the sterile injectable solution compositions comprising nor-UDCA and a s...
[163] Pharmaceutical compositions of nor-UDCA
[164] The present invention relates to the pharmaceutical compositions comprising nor-UDCA or pharmaceutically acceptable salt or ester thereof and the process for preparation. The present invention most preferably discloses the solid oral dosage form of nor-UDCA prefer...
[0164] The present invention relates to a controlled release injectable ondansetron formulation comprising ondansetron or pharmaceutically acceptable salt, derivative or metabolite thereof which releases ondansetron over a period of at least 2 days period from the date of administration and the process for preparati...
The present invention discloses liquid dosage forms of apixaban in the form of aqueous & non-aqueous solutions for oral administration. The formulations of the present invention can include higher amount of apixaban with lower amount of solvent and/or vehicles.
Registered Trademarks
[Class : 5] Pharmaceutical And Veterinary Preparations
[Class : 5] Pharmaceutical And Veterinary Preparations
[Class : 5] Pharmaceutical And Veterinary Preparations
View +45 more Brands for Shilpa Medicare Limited.
Charges
17 September 2019
The Hongkong And Shanghai Banking Corporation Limited
50 Crore
20 March 2019
Lakshmi Vilas Bank Limited
10 Lak
26 February 2019
The Hongkong And Shanghai Banking Corporation Limited
100 Crore
03 October 2016
St Helen's Nominees India Private Limited
99 Crore
09 September 2014
Citi Bank N.a.
80 Crore
15 October 2010
Standard Chartered Bank
65 Crore
04 April 1991
Karnataka State Financial Co.
5 Lak
02 November 1990
Karnataka State Financial Co. .
6 Lak
07 February 2019
Axis Bank Limited
18 Crore
20 March 2019
Lakshmi Vilas Bank Limited
10 Lak
15 February 2019
Hdfc Bank Limited
30 Crore
01 March 2019
Lakshmi Vilas Bank Limited
9 Crore
08 March 2017
Axis Bank Limited
10 Crore
12 January 2017
The Hongkong And Shanghai Banking Corporation Limited
50 Crore
18 March 2011
Standard Chartered Bank
15 Crore
03 March 2017
The Hongkong And Shanghai Banking Corporation Limited
50 Crore
21 March 2012
Standard Chartered Bank
20 Crore
21 March 2012
Standard Chartered Bank
30 Crore
25 January 2014
Lakshmi Vilas Bank Limited
13 Crore
12 September 1988
Karnataka State Financial Co.
30 Lak
31 May 1989
Karnataka State Financial Co.
5 Lak
07 June 2005
Lakshmi Vilas Bank Limited
4 Crore
23 September 1999
Lakshmi Vilas Bank Limited
80 Lak
29 September 1999
Lakshmi Vilas Bank Limited
80 Lak
22 January 1999
Lakshmi Vilas Bank Limited
30 Lak
14 November 1991
Lakshmi Vilas Bank Limited
15 Lak
23 February 1999
Lakshmi Vilas Bank Limited
70 Lak
17 May 1996
Lakshmi Vilas Bank Limited
8 Crore
08 May 2010
Lakshmi Vilas Bank Limited
20 Lak
09 February 2008
Icici Bank Limited
40 Crore
10 August 2007
Icici Bank Limited
41 Crore
09 April 2008
Axis Bank Limited
20 Crore
28 May 2009
The Lakshmi Vilas Bank Limited
20 Crore
31 July 2007
The Karnataka State Financial Corporation
60 Lak
24 March 2008
State Bank Of India
12 Crore
24 August 2007
State Bank Of India
4 Crore
13 August 2021
Axis Bank Limited
6 Lak
10 March 2021
Standard Chartered Bank
73 Crore
08 February 2021
Hdfc Bank Limited
50 Crore
26 June 2020
Axis Bank Limited
100 Crore
11 May 2020
Canara Bank
15 Lak
03 December 2019
Hdfc Bank Limited
100 Crore
21 November 2019
Canara Bank
2 Crore
04 August 2023
Others
0
27 March 2023
Standard Chartered Bank
0
27 February 2023
Axis Bank Limited
0
29 September 2022
Idbi Bank Limited
0
19 February 2022
The Hongkong And Shanghai Banking Corporation Limited
0
10 March 2021
Standard Chartered Bank
0
08 February 2021
Hdfc Bank Limited
0
03 December 2019
Hdfc Bank Limited
0
03 October 2016
Others
0
03 March 2017
Others
0
08 March 2017
Axis Bank Limited
0
11 May 2020
Canara Bank
0
26 June 2020
Axis Bank Limited
0
13 August 2021
Axis Bank Limited
0
01 March 2019
Lakshmi Vilas Bank Limited
0
09 September 2014
Citi Bank N.a.
0
31 May 1989
Karnataka State Financial Co.
0
07 February 2019
Axis Bank Limited
0
21 November 2019
Canara Bank
0
17 September 2019
The Hongkong And Shanghai Banking Corporation Limited
0
20 March 2019
Lakshmi Vilas Bank Limited
0
20 March 2019
Lakshmi Vilas Bank Limited
0
15 February 2019
Hdfc Bank Limited
0
26 February 2019
The Hongkong And Shanghai Banking Corporation Limited
0
15 October 2010
Standard Chartered Bank
0
08 May 2010
Lakshmi Vilas Bank Limited
0
10 August 2007
Icici Bank Limited
0
24 March 2008
State Bank Of India
0
09 April 2008
Axis Bank Limited
0
09 February 2008
Icici Bank Limited
0
24 August 2007
State Bank Of India
0
17 May 1996
Lakshmi Vilas Bank Limited
0
23 February 1999
Lakshmi Vilas Bank Limited
0
23 September 1999
Lakshmi Vilas Bank Limited
0
14 November 1991
Lakshmi Vilas Bank Limited
0
04 April 1991
Karnataka State Financial Co.
0
12 September 1988
Karnataka State Financial Co.
0
22 January 1999
Lakshmi Vilas Bank Limited
0
07 June 2005
Lakshmi Vilas Bank Limited
0
02 November 1990
Karnataka State Financial Co. .
0
25 January 2014
Lakshmi Vilas Bank Limited
0
07 August 2012
Others
0
21 March 2012
Standard Chartered Bank
0
21 March 2012
Standard Chartered Bank
0
18 March 2011
Standard Chartered Bank
0
19 January 2011
Department Of Biotechnology
0
28 May 2009
The Lakshmi Vilas Bank Limited
0
29 September 1999
Lakshmi Vilas Bank Limited
0
12 January 2017
Others
0
31 July 2007
The Karnataka State Financial Corporation
0
04 August 2023
Others
0
27 March 2023
Standard Chartered Bank
0
27 February 2023
Axis Bank Limited
0
29 September 2022
Idbi Bank Limited
0
19 February 2022
The Hongkong And Shanghai Banking Corporation Limited
0
10 March 2021
Standard Chartered Bank
0
08 February 2021
Hdfc Bank Limited
0
03 December 2019
Hdfc Bank Limited
0
03 October 2016
Others
0
03 March 2017
Others
0
08 March 2017
Axis Bank Limited
0
11 May 2020
Canara Bank
0
26 June 2020
Axis Bank Limited
0
13 August 2021
Axis Bank Limited
0
01 March 2019
Lakshmi Vilas Bank Limited
0
09 September 2014
Citi Bank N.a.
0
31 May 1989
Karnataka State Financial Co.
0
07 February 2019
Axis Bank Limited
0
21 November 2019
Canara Bank
0
17 September 2019
The Hongkong And Shanghai Banking Corporation Limited
0
20 March 2019
Lakshmi Vilas Bank Limited
0
20 March 2019
Lakshmi Vilas Bank Limited
0
15 February 2019
Hdfc Bank Limited
0
26 February 2019
The Hongkong And Shanghai Banking Corporation Limited
0
15 October 2010
Standard Chartered Bank
0
08 May 2010
Lakshmi Vilas Bank Limited
0
10 August 2007
Icici Bank Limited
0
24 March 2008
State Bank Of India
0
09 April 2008
Axis Bank Limited
0
09 February 2008
Icici Bank Limited
0
24 August 2007
State Bank Of India
0
17 May 1996
Lakshmi Vilas Bank Limited
0
23 February 1999
Lakshmi Vilas Bank Limited
0
23 September 1999
Lakshmi Vilas Bank Limited
0
14 November 1991
Lakshmi Vilas Bank Limited
0
04 April 1991
Karnataka State Financial Co.
0
12 September 1988
Karnataka State Financial Co.
0
22 January 1999
Lakshmi Vilas Bank Limited
0
07 June 2005
Lakshmi Vilas Bank Limited
0
02 November 1990
Karnataka State Financial Co. .
0
25 January 2014
Lakshmi Vilas Bank Limited
0
07 August 2012
Others
0
21 March 2012
Standard Chartered Bank
0
21 March 2012
Standard Chartered Bank
0
18 March 2011
Standard Chartered Bank
0
19 January 2011
Department Of Biotechnology
0
28 May 2009
The Lakshmi Vilas Bank Limited
0
29 September 1999
Lakshmi Vilas Bank Limited
0
12 January 2017
Others
0
31 July 2007
The Karnataka State Financial Corporation
0
Documents
Form AOC-4(XBRL)-04012021_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-29122020
XBRL document in respect Consolidated financial statement-29122020
Form MGT-7-30112020_signed
Optional Attachment-(2)-24112020
List of share holders, debenture holders;-24112020
Copy of MGT-8-24112020
Optional Attachment-(1)-24112020
Form CHG-1-19102020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201019
Form MGT-6-17102020_signed
Instrument(s) of creation or modification of charge;-17102020
Optional Attachment-(2)-17102020
Particulars of all joint charge holders;-17102020
Optional Attachment-(2)-13102020
Optional Attachment-(1)-13102020
-13102020
Particulars of all joint charge holders;-08102020
Form CHG-1-08102020_signed
Instrument(s) of creation or modification of charge;-08102020
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201008
Form CHG-1-06102020_signed
Particulars of all joint charge holders;-06102020
Instrument(s) of creation or modification of charge;-06102020
Optional Attachment-(1)-06102020
Form DIR-12-06102020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201006
Notice of resignation;-05102020
Evidence of cessation;-05102020
Instrument(s) of creation or modification of charge;-03102020
